<SEC-DOCUMENT>0001818382-23-000112.txt : 20230814
<SEC-HEADER>0001818382-23-000112.hdr.sgml : 20230814
<ACCEPTANCE-DATETIME>20230814070502
ACCESSION NUMBER:		0001818382-23-000112
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230814
DATE AS OF CHANGE:		20230814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		231166184

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20230814.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:d8be495e-c9e5-4aa3-bfc8-40170bac981c,g:1518ac05-0d61-4f72-a272-39a8b4608a58,d:ddea7a6daeab4cc49211e0a2b55f757d--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20230814</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20230814.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iddea7a6daeab4cc49211e0a2b55f757d_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 14, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Humacyte, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iddea7a6daeab4cc49211e0a2b55f757d_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;14, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June&#160;30, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="iddea7a6daeab4cc49211e0a2b55f757d_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20230814xexx991.htm">Press release, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20230814xexx991.htm">August 14</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20230814xexx991.htm">, 2023.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iddea7a6daeab4cc49211e0a2b55f757d_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  August 14, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20230814xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iae73eba951574274b23f3701779e6369_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:316px"></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Quarter 2023 Financial Results and Business Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Enrollment in Phase 2&#47;3 V005 Trial of HAV&#8482; in Vascular Trauma Repair&#59; Top-Line Results on Track for Q3 2023 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results from Vascular Trauma Humanitarian Program in Ukraine Highlighted at 2023 Military Health System Research Symposium</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference call and live webcast at 8&#58;00 a.m. ET today </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</font></div><div style="margin-top:16pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DURHAM, N.C., August&#160;14, 2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tissue at commercial scale, today announced financial results for the second quar</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ter ended June&#160;30, 2023, and highlighted recent corporate accomplishments.</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte has made significant strides in the first half of 2023 in advancing our universally implantable Human Acellular Vessel&#8482; (HAV) across our clinical development programs,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;Notably, we are excited that enrollment in the V005 trial in vascular trauma repair is now complete, and activities to report results are underway. We remain on track to report topline clinical trial outcomes in the third quarter of 2023, followed by a planned Biologics License Application (BLA) filing for the vascular trauma indication with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2023. We are also proud that our humanitarian efforts in Ukraine have resulted in successful outcomes to date, saving lives and limbs in a wartime setting. Finally, we are pleased that the potential of the HAV to resist infection was featured in a recent publication in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Vascular Surgery &#8211; Vascular Science</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, adding to the growing body of literature supporting HAV use in multiple indications. We look forward to building our momentum throughout the second half of 2023 as we advance toward the expected regulatory submission in our first indication.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Recent Corporate Highlights</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical and Regulatory Updates</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Completed enrollment of Phase 2&#47;3 clinical trial of HAV in vascular trauma repair</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In July 2023, the Company announced enrollment completion in its Phase 2&#47;3 trial of the HAV in vascular trauma repair (V005). The V005 trial is a single-arm, open-label, pivotal study of patients suffering from vascular trauma injuries, conducted at Level 1 Trauma Centers in the U.S. and Israel. The primary efficacy assessment is based on a 30-day HAV patency in patients who have vascular trauma of the extremity, as compared to historic benchmarks reported in literature. The completion of the V005 trial enrollment comes on the heels of Humacyte receiving the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for the HAV in urgent arterial repair following extremity vascular trauma in May 2023. At the time of completion of target enrollment in V005, a total of 68 patients in the trial had received the HAV, of which 51 comprise the primary efficacy analysis. Results from the V005 trial are expected in the third quarter of 2023 and are intended to support a BLA filing for the vascular trauma indication with the FDA planned for the fourth quarter 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In April 2023, Humacyte also announced enrollment completion of a Phase 3 trial of the HAV in hemodialysis access. The Phase 3 trial, conducted in the U.S., is designed to assess the safety and efficacy of the HAV in establishing vascular access for hemodialysis patients with end-stage kidney disease, as compared to autogenous arteriovenous (AV) fistulas. Efficacy assessments include conduit patency and useability of the conduit for dialysis during the first year, with top-line results expected in 2024. The rate of dialysis-related infections in both HAV and fistula subjects will also be tracked as a secondary endpoint.</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentations and Publications</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Presentation of success in treating wartime injured in Ukraine</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Results of the use of the HAV under our humanitarian aid program to treat war-induced vascular trauma injuries in Ukraine are being presented today at the 2023 Military Health System Research Symposium (MHSRS) in Kissimmee, Florida. The 19 patients treated under the program suffered from a range of traumatic injuries, including gunshots, shrapnel, blast injuries and accidents. Clinicians reported that the rate of success in treating patients with the HAV was high, with an observed 30-day HAV patency (presence of blood flow) of 95%, 30-day limb salvage of 100%, 30-day survival of 100%, and zero cases of infection of the HAV. Ukrainian clinicians concluded that the HAV has the potential to offer combat surgical teams an off-the-shelf and universally implantable therapy that is resistant to infection, potentially offering durable performance to military personnel and helping with limb salvage. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Publication supporting infection resistance of HAV</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In July 2023, a preclinical study providing a scientific basis for the low rates of infection observed in clinical trials of the HAV was published in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Vascular Surgery &#8211; Vascular Science</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This work compared the infection resistance of the HAV to expanded polytetrafluorethylene (ePTFE) grafts. The preclinical results showed that the bioengineered human tissue of the HAV had superior compatibility with the body's own neutrophil (immune) cells as compared to ePTFE, which may improve the ability of the HAV to fight dangerous infections.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advancement in Type 1 Diabetes Research</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2023, Humacyte and JDRF International (JDRF), the leading global organization funding type 1 diabetes research, announced a collaboration to advance the development of Humacyte&#8217;s Biovascular Pancreas (BVP) product candidate. Humacyte&#8217;s BVP is designed to use the HAV to enable the delivery and survival of insulin-producing islets as a treatment for type 1 diabetes. During 2023, the Company has been testing the BVP in primates. In recent experiments, the Company has observed that insulin-producing cells in the BVP survive for multiple weeks after implantation into the animal, and continue to make insulin after implantation. Humacyte considers these results to be extremely encouraging as they support the potential ability of the BVP to deliver a curative number of insulin-producing islets into diabetic subjects. Additional work in large animals is planned going forward, including using the BVP in diabetic large animals.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HAV and BVP are investigational products and have not been approved for sale by the FDA or any other regulatory agency.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash and cash equivalents of $114.6 million as of June&#160;30, 2023. In May 2023, Humacyte reported the completion of an up to $160 million funding arrangement with Oberland Capital Management, of which it has received $40 million. Humacyte believes that its cash and cash equivalents and expected funding from the Oberland funding agreement are adequate to fund operations past the anticipated timelines for potential FDA approval and commercialization of the HAV in the vascular trauma indication.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was no revenue for the second quarter of 2023 and six months ended June&#160;30, 2023. Revenue was $1.3 million for the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of 2022 and $1.5 million for the six months ended June&#160;30, 2022. Revenue for 2022 was related to a grant supporting the development of the HAV.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $20.5 million for the second quarter of 2023, compared to $14.7 million for the second quarter of 2022, and were $37.8 million for the six months ended June&#160;30, 2023, compared to $31.0 million for the six months ended June&#160;30, 2022. The current-period increases resulted primarily from increased personnel and external services expenses to support expanded research and development initiatives and our clinical trials, including preparation for the HAV vascular trauma trial completion and planned BLA filing for the vascular trauma indication, and expansion of clinical development of the HAV in AV Access.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $6.2 million for the second quarter of 2023, compared to $5.2 million for the second quarter of 2022, and were $11.4 million for the six months ended June&#160;30, 2023, compared to $10.9 million for the six months ended June&#160;30, 2022. The current-period increases resulted primarily from increased personnel and external services costs, primarily driven by preparation for the planned commercial launch of the HAV in the vascular trauma indication.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income (expense), was net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $4.0 million for the second quarter of 2023, compared to net income of $55.4 million for the second quarter of 2022, and other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $10.4 million for the six months ended June&#160;30, 2023, compared to other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $57.3 million for the six months ended June&#160;30, 2022. The current-period decrease in other net income, and increase in other net expense, resulted primarily from the non-cash remeasurement of the contingent earnout liability associated with the August 2021 merger with Alpha Healthcare Acquisition Corp.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $22.7 million for the second quarter of 2023, compared to net income of $36.9 million for the second quarter of 2022, and net loss was $59.7 million for the six months ended June&#160;30, 2023, compared to net income of $17.0 million for the six months ended June&#160;30, 2022. The current-period increase in net loss resulted from the non-cash increase in other net expense, and increased operating expenses, described above.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net cash used was $35.2 million for the second quarter of 2023, compared to $36.5 million for the second quarter of 2022, with the current-year decrease in cash used related to proceeds from our Oberland funding agreement.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Humacyte Second Quarter 2023 Financial Results and Corporate Update</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Monday, August 14, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 AM ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58; 1-201-389-0920<br>Conference ID #&#58; 13739966</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Call me</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Feature (avoid waiting for operator)&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Click Here</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte&#8217;s 6mm HAV for urgent arterial repair following extremity </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vascular trauma also has received RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials&#59; the anticipated characteristics and performance of our HAVs&#59; our ability to successfully complete, preclinical and clinical trials for our HAVs&#59; the anticipated benefits of our HAVs relative to existing alternatives&#59; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; the timing or likelihood of regulatory filings and approvals&#59; timing, scope, and rate of reimbursement for our HAVs&#59; the outcome of our ongoing discussions with the FDA concerning the design of our ongoing V005 Phase 2&#47;3 clinical trial, including determination of trial size, and the scope of any approved indication for our HAVs&#59; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those included under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, filed by Humacyte with the SEC and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LifeSci Advisors LLC</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-617-435-6602</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Humacyte Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rich Luchette</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Precision Strategies</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-202-845-3924</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">rich&#64;precisionstrategies.com</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iae73eba951574274b23f3701779e6369_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant revenue</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,818&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,862&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,731&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,832&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,243&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,828&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,731)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,531)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49,243)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,294)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,353&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense) (net)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(954)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,281)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,399&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,432)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,330&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) and comprehensive income (loss) </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,706)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36,868</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59,675)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,036</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,361,501&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,005,651&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,312,785&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,004,874&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per share, diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,361,501&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,908,440&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,312,785&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,923,138&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="iae73eba951574274b23f3701779e6369_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,562&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,208&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,543&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,039&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,001&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168,106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,571&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current portion </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,388&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,457&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,248&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,614&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,853&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, net of current portion</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,336&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">106,989</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,374</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,466&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(486,213)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,538)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,117&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,928&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168,106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20230814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d8be495e-c9e5-4aa3-bfc8-40170bac981c,g:1518ac05-0d61-4f72-a272-39a8b4608a58-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20230814" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20230814">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230814_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230814_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230814_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20230814_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d8be495e-c9e5-4aa3-bfc8-40170bac981c,g:1518ac05-0d61-4f72-a272-39a8b4608a58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20230814.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3ca19a0d-c013-44ab-b1d4-cedb496e40b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_DocumentType_3ca19a0d-c013-44ab-b1d4-cedb496e40b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4b1f29a0-0480-4b22-a26a-78835b646f20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_DocumentPeriodEndDate_4b1f29a0-0480-4b22-a26a-78835b646f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c2d0c48c-6c4c-43a7-8b73-3fbdd017a941" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityRegistrantName_c2d0c48c-6c4c-43a7-8b73-3fbdd017a941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f34d4916-031f-4e81-95d9-ad2b2cdc2197" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f34d4916-031f-4e81-95d9-ad2b2cdc2197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_930c1215-7d01-423f-8932-7c2d294416d0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityFileNumber_930c1215-7d01-423f-8932-7c2d294416d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1cd7a567-3457-48ce-af91-ee4822930840" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityTaxIdentificationNumber_1cd7a567-3457-48ce-af91-ee4822930840" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1ddfc46d-790b-4f05-9938-1eed10bf83af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressAddressLine1_1ddfc46d-790b-4f05-9938-1eed10bf83af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_919bfbca-4482-4aaf-aadb-13c666f4d2ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressCityOrTown_919bfbca-4482-4aaf-aadb-13c666f4d2ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e5007df9-39f0-497f-906c-ab117dfb79d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressStateOrProvince_e5007df9-39f0-497f-906c-ab117dfb79d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7299f9b1-78df-4e9c-814a-d54a73faaf59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressPostalZipCode_7299f9b1-78df-4e9c-814a-d54a73faaf59" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_31311623-c405-40d1-8f9e-b89b99a62cc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_CityAreaCode_31311623-c405-40d1-8f9e-b89b99a62cc5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5bf35eb1-5e4d-42a1-a313-172b002915cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_LocalPhoneNumber_5bf35eb1-5e4d-42a1-a313-172b002915cd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_11452038-d0ff-42b9-bf66-7bad9015f13c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_WrittenCommunications_11452038-d0ff-42b9-bf66-7bad9015f13c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d21aa4dd-5996-49e2-b68a-f2323215f41c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_SolicitingMaterial_d21aa4dd-5996-49e2-b68a-f2323215f41c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6ae0c133-1ddc-47a5-8eae-1c91ac6dd987" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_PreCommencementTenderOffer_6ae0c133-1ddc-47a5-8eae-1c91ac6dd987" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_15e60956-ba06-4347-9974-98ac67ec32b1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_15e60956-ba06-4347-9974-98ac67ec32b1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_47ad052b-c808-4325-af60-f77320de1d6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_Security12bTitle_47ad052b-c808-4325-af60-f77320de1d6d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3237c21e-5add-42af-aaf5-23d2bc8c19ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_TradingSymbol_3237c21e-5add-42af-aaf5-23d2bc8c19ab" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e23cd559-3730-49f6-8e98-c36823e6600c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_SecurityExchangeName_e23cd559-3730-49f6-8e98-c36823e6600c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3bc31d8d-7b70-48e4-9e1f-7c067e1609d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityEmergingGrowthCompany_3bc31d8d-7b70-48e4-9e1f-7c067e1609d4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f055f666-8700-4f41-8e6b-35a50815b33b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityExTransitionPeriod_f055f666-8700-4f41-8e6b-35a50815b33b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_03d20983-ca01-40ab-bd88-9c28b947f4b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityCentralIndexKey_03d20983-ca01-40ab-bd88-9c28b947f4b4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_38427e4c-9d11-436e-a0ff-c81b242dc422" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_AmendmentFlag_38427e4c-9d11-436e-a0ff-c81b242dc422" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:to="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_22035756-4bab-400c-9629-f4a0dda9cef8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:to="loc_us-gaap_ClassOfStockDomain_22035756-4bab-400c-9629-f4a0dda9cef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:to="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3a18606d-93f4-45c5-97d8-2e533a2da0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:to="loc_us-gaap_CommonStockMember_3a18606d-93f4-45c5-97d8-2e533a2da0a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dc1f1350-7a62-4f75-bee7-75ceb06d3e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:to="loc_us-gaap_WarrantMember_dc1f1350-7a62-4f75-bee7-75ceb06d3e7b" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20230814_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d8be495e-c9e5-4aa3-bfc8-40170bac981c,g:1518ac05-0d61-4f72-a272-39a8b4608a58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_a94ddb02-ea4e-4d00-b1e5-5839d6750075_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2de25a9f-dd02-4493-994c-df10754fd47b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_149e390a-8bb0-4bce-9243-5d11b77a9bbc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_257ff2af-df4a-45fe-8465-b49239784a72_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_aa0d7b6f-3943-4c95-a45a-e3abbe208876_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_86d00d12-9f18-45ed-ba1e-96633632e171_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7b816723-dca4-4223-9279-6f498da025e0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_95d34286-90e7-4096-b557-2994449c5625_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6a2fb183-5388-4fe6-9cc9-735c0cea25ea_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6e4475cc-f7d8-4196-a239-e56d5bf80cca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_194ae797-1034-4ee9-b52e-f0660184877c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_16d0aec2-a6dd-489c-96f2-4fe7e5690e21_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_c0c7470b-e56e-4a98-8b99-c822bad335a8_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_77cf60c1-cdf0-47ea-83d0-9e70f0cdc262_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9e8413a5-9cb5-404f-8831-950ed52f55d1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e15a24a0-3c0c-40ef-a7c0-1d7e6ded2fe1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c7fdcffb-f4f6-44e5-8781-5b5e15fea971_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_927e02d5-231b-4c87-a261-aa5ea39bcec0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_79ccd4bb-8c2b-4c7d-8da7-49779c08998c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_19c5b573-a25a-40e9-8760-e616ae6e987a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4c5b03ea-a72f-43c9-ad4b-871c98d088a5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2269c40b-cac4-427e-bfc8-a732329d09af_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_2045ad9b-b1ee-45c7-9b96-c2ca8cfc1e2d_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_91d23db4-b444-4f69-9524-580380aa4ee7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7076d186-f7d9-467f-b907-4efaf2bb1c02_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_ea8c0bca-0f33-4f1e-b018-3878d9b16419_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2ab33483-54e1-4422-a640-13d4763b97b1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_920d62bb-ab1e-4bcd-bf4b-87f014455fdb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b0885008-7845-484d-890a-5b97ccbcb81d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20230814_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d8be495e-c9e5-4aa3-bfc8-40170bac981c,g:1518ac05-0d61-4f72-a272-39a8b4608a58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20230814.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_61c71de1-1cd6-4be8-a897-92f4ecd343de" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_61c71de1-1cd6-4be8-a897-92f4ecd343de" xlink:to="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:to="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_22035756-4bab-400c-9629-f4a0dda9cef8" xlink:to="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3a18606d-93f4-45c5-97d8-2e533a2da0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:to="loc_us-gaap_CommonStockMember_3a18606d-93f4-45c5-97d8-2e533a2da0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dc1f1350-7a62-4f75-bee7-75ceb06d3e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bee5391f-ff93-4cfb-97e1-d74a787ee5c6" xlink:to="loc_us-gaap_WarrantMember_dc1f1350-7a62-4f75-bee7-75ceb06d3e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_e61a6d79-2cd3-41c4-a645-478430642d79" xlink:to="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3ca19a0d-c013-44ab-b1d4-cedb496e40b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_DocumentType_3ca19a0d-c013-44ab-b1d4-cedb496e40b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4b1f29a0-0480-4b22-a26a-78835b646f20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_DocumentPeriodEndDate_4b1f29a0-0480-4b22-a26a-78835b646f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c2d0c48c-6c4c-43a7-8b73-3fbdd017a941" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityRegistrantName_c2d0c48c-6c4c-43a7-8b73-3fbdd017a941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f34d4916-031f-4e81-95d9-ad2b2cdc2197" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f34d4916-031f-4e81-95d9-ad2b2cdc2197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_930c1215-7d01-423f-8932-7c2d294416d0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityFileNumber_930c1215-7d01-423f-8932-7c2d294416d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1cd7a567-3457-48ce-af91-ee4822930840" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityTaxIdentificationNumber_1cd7a567-3457-48ce-af91-ee4822930840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1ddfc46d-790b-4f05-9938-1eed10bf83af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressAddressLine1_1ddfc46d-790b-4f05-9938-1eed10bf83af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_919bfbca-4482-4aaf-aadb-13c666f4d2ef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressCityOrTown_919bfbca-4482-4aaf-aadb-13c666f4d2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e5007df9-39f0-497f-906c-ab117dfb79d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressStateOrProvince_e5007df9-39f0-497f-906c-ab117dfb79d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7299f9b1-78df-4e9c-814a-d54a73faaf59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityAddressPostalZipCode_7299f9b1-78df-4e9c-814a-d54a73faaf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_31311623-c405-40d1-8f9e-b89b99a62cc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_CityAreaCode_31311623-c405-40d1-8f9e-b89b99a62cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5bf35eb1-5e4d-42a1-a313-172b002915cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_LocalPhoneNumber_5bf35eb1-5e4d-42a1-a313-172b002915cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_11452038-d0ff-42b9-bf66-7bad9015f13c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_WrittenCommunications_11452038-d0ff-42b9-bf66-7bad9015f13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d21aa4dd-5996-49e2-b68a-f2323215f41c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_SolicitingMaterial_d21aa4dd-5996-49e2-b68a-f2323215f41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6ae0c133-1ddc-47a5-8eae-1c91ac6dd987" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_PreCommencementTenderOffer_6ae0c133-1ddc-47a5-8eae-1c91ac6dd987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_15e60956-ba06-4347-9974-98ac67ec32b1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_15e60956-ba06-4347-9974-98ac67ec32b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_47ad052b-c808-4325-af60-f77320de1d6d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_Security12bTitle_47ad052b-c808-4325-af60-f77320de1d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3237c21e-5add-42af-aaf5-23d2bc8c19ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_TradingSymbol_3237c21e-5add-42af-aaf5-23d2bc8c19ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e23cd559-3730-49f6-8e98-c36823e6600c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_SecurityExchangeName_e23cd559-3730-49f6-8e98-c36823e6600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3bc31d8d-7b70-48e4-9e1f-7c067e1609d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityEmergingGrowthCompany_3bc31d8d-7b70-48e4-9e1f-7c067e1609d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f055f666-8700-4f41-8e6b-35a50815b33b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityExTransitionPeriod_f055f666-8700-4f41-8e6b-35a50815b33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_03d20983-ca01-40ab-bd88-9c28b947f4b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_EntityCentralIndexKey_03d20983-ca01-40ab-bd88-9c28b947f4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_38427e4c-9d11-436e-a0ff-c81b242dc422" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_2a232ac6-0dac-4709-89d9-a60d6872d815" xlink:to="loc_dei_AmendmentFlag_38427e4c-9d11-436e-a0ff-c81b242dc422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M;5:?]5";A.'$.M7Q-:JCJU1'5JH.KT#_J[A\3%-P4X_7 @        !) L+
MAJH"?4JP-MQ;&>&M#O-Z6!BV6!.&0\M4 >XJ_Z6J8QO5-V)T>%T
MD!@@#,R0UU)IY[67?#47?307=JMI"L.QU;@P'%BL\ENH.KY.77@+M $
M  "0+B ,#"A(U<7L547MU7 E#/L6J/:ZJ2X<U.BT,+<!        D"(@#+30
M**G48'7,?DWT/@TF#.%LA6'_HOO"X.NJ/+!"U5 -S@        !(#A"&IE'6
M4?%'5;$'-/P)@\]\I?<\>641. ,        @+4 8FD!1IX\_(HOSYUT8=LU5
M[IR#G $64 (        D! B#-9 M7#E2'Q\@%T88O&<K/6?+%?5PG@$
M  "0"B ,%J'TAN03-5<"ZN(#!#K#@(1AYRRE]UPYWA4         $ D0!HND
MGZM).%@MO##LF*$\OEF)]P8         Q "$P3Q%UV4)!RNL"$,DG\*P?88\
M)PWV9P        #$!X3!#%J5/O%(*4_"<-"*,,RY+PR>TY4[IL&%20
M (#X@#"8X69$V=5#)2R$(9@[8=@V37DE1(OW#         "$!80!1UFO33I4
M( 5AV#8#3C(         (@/"@)-QOB3Q<"%=8=C%HS!LG:+,3H-M&0
M   Q 6%X"$I/)1\K^$L8RL41AID/A&'W?!7>10         0$!"&ARBX5IEX
M.,]68=C,F3!LF0I7)0$       !B L+P$.FG<YL0!C^6PG!T%2MAF*PLRH2K
MD@        #1 &%XB)3C62R$(6PGC\(0N$.-]Q(         A *$X0&R2D72
M$5(8:GD4AH46A6'[7\*P!39D         ,0#A.$!1=<JN!2&C=P(P]8I( P
M      " :(@C#)K*<.6=-?+T*8KK<Y6YN_6R+/P>8I 1FG=/&'*;%H8];(5A
M.6-AV#()A $        0#:&%@5(6-"3^TA#S>7WT5_717>HN?U=[N7M-5$_Y
M[4T&O0:_M[!</Y.#A"%)8L+@ 6<8         /$05!@H3;G\2C=9S'](8:B)
M^KGANKN!$G-%H/2S69:$(=Y?R9\P[/D3A $       "0*((*@RICG"SV$TO"
M4'VIC[HL$F\C('P(PTD0!@       ,">$4X8*'5Y0]Q'UH6A-GX\WDQ F K#
M14&$82O,80        #$0SAAT)8=E\=U-"<,W4S"4'6I'Z5MP%L*Q</"4"R*
M,'@1PK 9-GL&        Q$,X8= 4>=$1!IVB!&\I%.GG<B4H#+ / P
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M%@8CE*9"4WY6G>^CRM^CK8Y#_XW?0R3DU2IVPA"Z@WMAV#9%KE;@/00
M    (1%'&*1,RLD"0A@:1!&&_<M %P        "1 6' *;]3SYDP;& O#%NG
MR^NJ8+HS        (#(@#&9(.4Y#&'S9"L,R6L)P>(,*[Q8         " X(
M@QFJ\Q0)AXO8",,VCH1AIEP'NR\         $@"$P3PWSE=@PA#GSZ,P^+H^
M$ ;/6?);"3J\0P         @!B ,YM%KJ:1CW C#B;7,A"%HEQKO#0
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M"$.HKSHK18]7Y)GZ&NK(%M7,7@U3>\JF_""C(PRF3.W9$+A;K=7 9P$
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M&(*$%0:E7'QAF-+#_K9B &$      $: ,-@C]0WR?W>=;'QID E,G.=IFL^
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M0O)MO+HY0!B80E,8BDNK\):29-7FHV3G&>79M@-=IGJ</!?;(*-U249-;4/
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M0L-CK_?A::J5">D* Z655<;-*;\PLDEAR M959UQ 6_/A/1SZ:R%(<);K=.
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M_ D]J)G56]Y8&*;8)@PH*\?Q,@=?2$ 86-"M/ZUQV/?]7?&6DN3 L0MDY\F
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MC5>W 'IOA$8FCYFQA>EB3606KMZ/5^>3N\)@T)3H4_Y." #3W!4&JF05?@1
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MSK-M!\Y:["-7J/ ^B0<( ]!" 6$0A;5;CS_;5KC+0Q]OXS37?4]=O1SOQSU
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M7TK!NP4 O"&:,,@3^S$7AHE-"D,.(0S*JG+\V%P0?]#\I&?.A:&RF,?-J@$
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MD5_(RY75 , (T82!TFMDL=];%H:!G B#HJH,/S!W7#FFY548/*?)=?!K @
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MBJ^.'LQ0&!8^$(;SFY65>7A182F^K0OQ4M 1AH,/"\/^A8H[B;Q/T08
M    IDA(& QWYT#7RC+65$09A6$P?6&H3 _2:R5QZ;]>9[@5K0O:K*0I#/Y+
M% E!6K@,"0       ) FTA(&(SI93OV-#551OS8I#/FA2ZO2 [6*&KR$V"!M
MR$O5Q9U4!VY4FA6&PRL4D0'JVPF@"@       ("DD:(P&*&T,E79Y?I;/M57
MEU9<FO&7,$PIO;2HXLK6VHQ 1=EU7C=RYHJ&*JKXCCXW39>;JLM)U15GZ>LJ
B*/Q.         "!)_A^6L1,=D>"BX@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140437136327120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 14,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>huma-20230814_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20230814.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-08-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "@. Y7<A872Q4%  !R%@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;,68;T_K-A3&OXK574V;!#1VZ#\&E4J!@>Z%VU'ND#;MA9NXC4429[9#Z;??
M<=HFH)N>%'2EO6F3U'[ZL\_Q<QR?+I5^,I$0EKPD<6K.6I&UV4F[;8)()-P<
MJ4RD\,M<Z81;N-6+MLFTX&'1*8G;S/.Z[83+M#4\+9Y-]/!4Y3:6J9AH8O(D
MX7IU+F*U/&O1UO;!O5Q$UCUH#T\SOA!38;]E$PUW[5(EE(E(C50IT6)^UAK1
MDW.?N0Y%BS^E6)I7U\0-9:;4D[NY"<]:GB,2L0BLD^#P]2S&(HZ=$G#\NQ%M
ME?_I.KZ^WJI?%8.'P<RX$6,5/\K01F>M?HN$8L[SV-ZKY;78#*CC] (5F^*3
M+#=MO18)<F-5LND,!(E,U]_\93,1^W1@FP[%1+37?U107G#+AZ=:+8EVK4'-
M711#+7H#G$Q=5*96PZ\2^MGA6#T+3280@-.V!3WWM!UL^IZO^[(=?4?YXHC0
MXP/"/.:_[=X&C)*%E2RLT/-WZ%VF5MH5N4G7R>:"]O<7:$-NK$C,/W6 :\'C
M>D&7T2<FXX$X:T'*&J&?16OX\T^TZ_V&X/HEKH^I#R]4D$-^6O*PRFIG#^_>
M/_R,0!R7$,?[04R$EBHDEVE((!%J>7"E,II-X>R4:!U4<!/.>[&0QFH.C'<\
MJ07#=:[SA <K*PX@,X(C!*Q;@G7W 0,UI3.EBTP[(%,+TT:4)F.5IU:OX#NL
MI<7%+RX1PEY)V-N'\$K&@MSER4SH.A!<P_/HH3_H^ SAZ9<\_7UX'O@+N0DA
MV^1<!NL%NIL.5^QW#FFOZ_<Z P1O4.(-]L$;A2&L<G.PO2"%>7Q-:Z.(*[(.
MZY!+;B!GE;81&7.MH TGU^#R2[XBG6.$FWJ5^WKO(A^[.\C!![5,:PT9E[O(
M=<23 PSM56&@[T(KU\=$JV>9!O4% ]>\&V-H59V@J*]_AS91QO*8_"6SG8NV
M09'U>A3S/%H5!8K;>A'!$6R0=J/@ @.*+0E:%0:*^_D7%<"<3"*58A[2(.)3
M_W#0]=&IJ>H!Q8W\44MK10H3DR1YNG$04TN%"\UY; 2&5%4"BKOU%%9U(*U,
M%^06TEM+'M?RX"J-/)7O4]RT)UH<!C ] M;7>F\ATA V:%_G\QWQP_4:R:H*
M0''#_H[LQI@<R!H!<=E&P*H&T+V*P&4B],+%\W=0<,ZMDHRGJUHT7-#J'"-C
ME<FSO4S^\H4\P#;(R*)PKO=KM7M:7*UIQECE\&POAQ]#-#58Q0T$\H5\%K5S
MU2#EP6ZC3_M^']MML%<O K@=CR##PB++KF*^J.7!!1HGJ?)SUN#GD/,0KJE5
MP=,!R;@FSSS.!?GD';E!DPR2WT1<UUH]KOW!]Q-6E0!V_,-?J-!Z\%'BJD0P
MW-D?I(4MKYH3RGZ9_4JF(LBA:-1G)*[TP;B]Y:[J",,K "SLT)G.=)7,5&T)
M:1"X_G8[PDBJ"L)PQ]].&=A-$/%T(7:^=34(W8VF%Z,_,*:J=C#<Y.]%*$3"
M9Q#:1Z[=JR!LV@0/(K*,%#Q<KA\2\2)T($W1$%*6N*U+$2.7$:\#2K@E/-VV
M%R33,B@:?:+TJ./5CA9%_&AB5]6)#7[X4D3+TT</-ZJJY>-UYAU+L4'I_PW_
MV^%7Q=''*UKSBFX0<"OZ$4.IJJ&/%[/]EW2#T.XEW7YU@NA.8V^YVT09$HLY
M*'E'/3!;O3[@7-]8E16'BC-EK4J*RTAPV FZ!O#[7"F[O7'GE.4Q\_ _4$L#
M!!0    ( * X#E>?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;
M,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VA
MR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;
M)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/
M3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O
M_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_
M/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:
M^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_
M[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!
M6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<
M'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72
M[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'
M')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^
M6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]
M?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1
M/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\E
MTWLJ.?]74_P$4$L#!!0    ( * X#E>7BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ H#@.5QE%%?4W 0  )P(   \
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ H#@.5V60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( * X#E="\<D*[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( * X#E>97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ H#@.5W(6%TL5!0  <A8  !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( * X#E>?H!OPL0(
M .(,   -              "  5D-  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  +$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20230814.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="huma-20230814.htm">huma-20230814.htm</File>
    <File>huma-20230814.xsd</File>
    <File>huma-20230814_def.xml</File>
    <File>huma-20230814_lab.xml</File>
    <File>huma-20230814_pre.xml</File>
    <File>huma-20230814xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "huma-20230814.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "huma-20230814_def.xml"
     ]
    },
    "inline": {
     "local": [
      "huma-20230814.htm"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20230814_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20230814_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "huma-20230814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20230814",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20230814.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.humacyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20230814.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001818382-23-000112-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-23-000112-xbrl.zip
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MW?-K<M6]O+BZWJ'6V&R[EYE(,_#AB(Q)CWF8*R!.A<2".+4#_QV)@[T'X7K
M<.N9X)+#K-VQ-X!0E)%33\+VB=.L5/=(>:_X4PH&=%-QLU<LB84D!]/OC(*C
MRE))V"TF^(1J9OZ[EI8XLKW(72H?N*L]X^5D@ ^_F!!LR0$.,WTZ,2>P 9-%
ML]R T3[-;C+8CU,MJ>3AL\KK#WOS@O9F[PS'MEFR*W;#4TQKRG-HF;(DQ,^_
M9D/J320KD;/(LS;FR'V1_8/NF(*J0G!1Y,4,3$)3DB;,PT#>)SPB7*8$E!MH
M /'NAZ#MNZ"])CQ77,NM5#;"\[Y,6]V&*]:QP)3*;C)&.J\*RUVL:X1_^Q#/
M?HS&!'48"_ 8U!&0RN=UXBR28M*)_67;CR=*F%F3+!'Q+<XS-_I5<$]82$=4
ML+6Z-2?#=X?A#SQDT+D/6C7'ECJS<<Q*LU99/;+YWM%U3<=G>6K:4TRYC+M#
M" %KIE,_K-1KS7N1]]QB#3K[VUM_A<(#)9<8<,5RP 3Y+\0QJ<]U) ;1%^8$
M^*(<JZ[BAD;\?^K[NY?@JAWB P]\>(IG$02EBV@6>6M0GEE75L\BW6$2QA,F
M%)F71:,0\,T=$/=U.2!NQ:I6:\_N*;S0M-6FU7"V<DN7>?9P$YX-6;""\YFV
MW\,$]+;&X-3W!4O3_'\?83YG:@CJ1MNMN372I:DDY[&0 ]*A ISSB))?8<D1
MG9!:]?Y(;P-%L>K;/\JDJ%*J7>B6YS'*.0$Z\/%"7,>CF>/7 ,<O$P,Z+#VO
M(U/$V+M#U[:YZR6D*>-](2[!:>:JHDECKFFTSSL_O+]BG%W&$&B$_^:)CD+R
M[+\-(E^O.^L3BD]3IGOG .3(P(Q/(H!W>$)#PL;,RR2_Q400^ $L?6MN#U =
M0/#98[V:^_*7#YR?[8N9/-A<;% EGPI&EP3%,=I-9R4Z>K>M&OL8 T-<#N+H
M3OSJN$:[XE3,YF%E\^3^WJ12YSGBO_[<<)WZ44HD"UF"<))( 5HB(&UAAB)#
M*"#W#C_N/GN^&1N=QY*<)EAIA6+SB'J<G=#G0RR E?)<MU 9*/A*M2X$R@1$
M']Z!0XWVE(3H .I3KXU)M"/8.@/F?555]S1)1 Q*'>/Z?CPF?1;&(X0-&Q$#
MI&'^1@(>(@OR%/A1LL@'F&4,8 ^S4-*(Q5D:3D@*H6 :3-3(?$#<!SKFF0 ]
MY<*)00;S #ZCR;0M@!@O'N$X3.QQ#*O3UA:8W*L \KYPS;7LNOOL@5[ST#IT
M&R^<:7ZR/_P%)L;)TZ=9Y\V-QQ?!)? LIFJR*,]7I ]6ECL5HQV_C5"B&($Y
M6@"&1;R09*'&XBH#<:I":*LE52[7+F#)PH%3)YT/5\2MV!9T+/"4OA,FZ\6J
MC!B6_ 2:%-1I^#"'5=\XA\UQ0H8Y4E;9RZE2<.,6.&RI)&;&7U707JKG]\MB
MEX*A#L/[)*H<#<VPN @"=(<?8K7:&V<UP(WI+2#G0:WF5'W3/>B_VXSQ=-\?
MK)=C]RQ-,R:V8L##'PQXAP$KS*P>>)LQ8-[W"8F(??..WW =S2[BN06W3 =8
M3$"(EA35RRJMEP=<P&C[&U\UFU:CVGA4@9!C-38,A+9KJ]J'SU\?]-HV6]DL
M<GU3Q4S7>,]:USA[ ^+A)<,MK->2.GD3Z!!4I21[DV$_#@^VROR_.62<Y[6P
MBC78U(:#JAT-N#=0>?ZY3M[&A<PUK%+ Q79JKTY1'G'NYBZ%T-J&31RWK\1M
MYCO6C;:^6$W4M=X22:@@MS3,&/FS<C(<DN#-X\'3BOXV8,SOC"*YF&LIGY&C
M8;1__?SI] >F7X#WIR& OC1PM^85E<MRN:O3U%>*SFGJTS^T?)!/5'QEDGS\
M>/^I_D/:AWI?;T0,X8F9X\OS& N"-T. RB;*Q[6-]A7S&1LJWS=_1" M:6T_
M&L3PXTC_B ?BPN.IZAA@X6/$M%)"Z["HP0B5!)"1]V=XINZI3G]V'*MF/T*R
M'B36)B+W71&\4+>YCM9M7WZ0X!O*W+9*SW6?J/3V/)@_BWS,&S'2GQ!/'=3"
MOKZ"LF&JZ/K.*2I/E2X!6&_0)0?V&<D!II\2/%FE*?%9 $NH.UGZ0,>N3>/_
M.Z<Y^@)JA1S@"7W]2!WJ3#MS=9LKP=M<>!BN<UANWW0+YBJZU3J;%/-9\W$+
MTUI[?F;>+4;Q<C7#-\O@/JJ*=0K"+PJ"C@:@*'DK138W@16C/7[LU=E=B5!P
MCU!@44VAA/&5$H4!R \+F8</%4:Q2J1E8+"Q%R Z+X3 Q^NX2J[I-WN4\<>U
MP@DNKAXX1%F, #9H$>P6C#[TXA&-/#P4HYZ'5YVP,SXVYU/AI[H$PE^7Q:L<
MT%D6;U'<K%?%CN/K&>[T5>^''WR[]]!TWU*8KR,)?N=AGRT3X1O5,RX^*)7$
MFN(MP4**]:,K3TS-MZGV9\^'T#Y$@IE</V2;>LN[KU9M]FA6W9B.&8AY8'O#
MS+Y@]*M) UBT1<,1G:1&^85?UOIF6K:XK.],LB%Q+=NUR!5+LU"J"N$+T(+Y
MJ1?H,O)AIN8Z,:A=;-BN?A&4-5"R53G<F36YB(A^24(KU^ES$B6R?)D?7+$T
M X5-07=CM33P-Z.ILB>@T57]'&!HKO9%CC,T%[HE!65"P.D%1)$_,G5WGF@C
M\\\LRNLF*[9>W2*G(-K)9.9'+2\*/P29B'@ZP!VA3S;@?2Y)LVDY:$G4D$XF
M!!Y6YB]YX"VV:<4?DFY^E0_F ->3@0L)%G/VK.7&'MN^$!*C!A[-'II5%HHJ
MYUA#MUANJVV\1AJ5$L+]O)N,2QC6AZ'R"/J,8'8 VK"(UX7=\Y#YZK-SI$@+
M]AOT%U.R,;/?C0W=YA+2C@XU$QS@@'R9Q<[Y:N]*Z%XL$6V16A@ H!N2EV:N
MK>G*HX#%E=7$=UV-$B:[6:)??E#XZ"/&%!MB-2A$8X&Z#06;R%^&\)9WDV8>
M>$;YA@J8:<-7#&VC@ ,Q=C2!ZP3U9"O-AL"1DZ,]4IM-RW:L!>4X>\%2:\U<
M7--]#XKPV:7'[/75^&%.W6HV-_/#MFNKU>K/?CQ;!ZZJ;?:$Q4N4+\U\F&^=
M<\HY<(7_=G3;(=-/S#[E@N>S4&6GQZ+O6>H)GBSY>T\Y=E@\$;)J2V="#QP+
M[91AB]4F>F$;,\B+9I:_-5J#X,6J\/3F?'"?=?S14BX.]H(]T4+'('?PCG:^
M05+PM/R8C<?-IF,-Y% 5&,Z]^Q+QE7MW7*:O'[+9(WUO IH\.%.PK IX<:K&
MJ=Z7JUF1W$#]>YKTO_0<+W"XO%\%OXY=W>-#P2)<#2&4"MFN+AS&L!MR22%T
M/,.T' @UWAQ_3R75+^<<X /\OI__02 (#C'</%-^/U%_.,C/WP1=."=Z^$#O
MF^4="\/-?;G)>M?5>%3>$R_$[5WB<V]N./?.?CD_O?Y\U7UM*;'%-Y7UX=<?
M&1=Y)F+3'%7!J9F?A1/BT0Q/NE2N45^,QF7Z$/@#P: AUL^$]MF A@'FB7 B
M96SS#IAORR(8HZ:CF1S$ H#SWV2JH69;=>=QE>#WUFQ;3O7Y+QM7K8;=?/Z]
M'EK-RF89E0T3&&L-;'.?+QD5A]18FM3YUW6W1,[..P5F<#O'\A%YA[5=5Y^U
M>:;GJO8P=L>WR%N$K+PMOF6Z9X^XK=C#_<>DM=;#??2;<+L#1Y^>E=,R.)U@
M#TXMTJ-H:1YSJ?,Y1*:XUOFY4C"[P##6[ZUGF;<'[[[QT:M!G*JPWH137@U$
MG0%GP<)IWH5Z$4V4B&[H3$]DR7MVR\(X45>$\T[JO.\:8J@T$T5LM/O@=E_B
M6'=]'%O6?_M4_<'4]O\!4$L#!!0    ( * X#E<=XKN E (  /T(   1
M:'5M82TR,#(S,#@Q-"YX<V3555MOTS 4?N^O,'G&3=++ED1K)[%I$E*!:6QB
M;\AQ3E)KB1UL9VW_/;9;JY<5MB(>H ^I<_Q]YWY.+BZ738V>02HF^"2(^U&
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MV=_PR\D39V!9^N75B]7E]D_[(/"K%_\%4$L#!!0    ( * X#E?"0#_:0PT
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M;J7V4]2O3UL?1(J>(REC9-XG7$ZKIC7%__*+ONZ63.NH+<4]O._J;NU 46'
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M>_--.$F,ANJW 2P-! KQOUYZG6GJ_QK@5"<&6#/&0\'$-T>B2,5#V%=BRJ]
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M6NOCLO:CXK)%!)VF@]6L6RU<>![E+* 1T"+34<Y9-$"1SN40Y0#>2FH=WOL
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MO"1>_L@#4BE;IL$7Z]*9W'?QG\,PG<R87XM:/Q3\IL8',-=S[H%S&3W;2\U
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M0F]EW,7358H8K.?EV<*?T3']D#A#$2^]FGP_,\&\CZ2<\1?MV"RX-&C/6QB
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M2P$"% ,4    " "@. Y7'>*[@)0"  #]"   $0              @ %H$
M:'5M82TR,#(S,#@Q-"YX<V102P$"% ,4    " "@. Y7S,?0!X (   #/@
M%0              @ $K$P  :'5M82TR,#(S,#@Q-%]D968N>&UL4$L! A0#
M%     @ H#@.5\) /]I##0  4W@  !4              ( !WAL  &AU;6$M
M,C R,S X,31?;&%B+GAM;%!+ 0(4 Q0    ( * X#E>OZD46+0@  -I    5
M              "  50I  !H=6UA+3(P,C,P.#$T7W!R92YX;6Q02P$"% ,4
M    " "@. Y7I="1<\@F   #FP$ &               @ &T,0  :'5M82TR
H,#(S,#@Q-'AE>'@Y.3$N:'1M4$L%!@     &  8 C0$  +)8      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
